Yosuke Horita1, Kyoichi Kaira2, Tomonori Kawasaki3, Yoshiaki Mihara4, Shinichi Sakuramoto5, Shigeki Yamaguchi5, Kojun Okamoto5, Shomei Ryozawa6, Yoshikatsu Kanai7, Masanori Yasuda3, Tetsuya Hamaguchi4. 1. Department of Gastroenterological Oncology, International Medical Center, Saitama Medical University, Saitama, Japan; york01@saitama-med.ac.jp. 2. Department of Respiratory Medicine, International Medical Center, Saitama Medical University, Saitama, Japan; kkaira1970@yahoo.co.jp. 3. Department of Pathology, International Medical Center, Saitama Medical University, Saitama, Japan. 4. Department of Gastroenterological Oncology, International Medical Center, Saitama Medical University, Saitama, Japan. 5. Department of Gastroenterological Surgery, International Medical Center, Saitama Medical University, Saitama, Japan. 6. Department of Gastroenterology, International Medical Center, Saitama Medical University, Saitama, Japan. 7. Department of Bio-system Pharmacology, Graduate School of Medicine, Osaka University, Osaka, Japan.
Abstract
BACKGROUND/AIM: Little is known about the expression of L-type amino acid transporter 1 (LAT1) and 4F2hc in gastroenteropancreatic-neuroendocrine neoplasms (GEP-NENs). Hence, we conducted a study to verify the clinicopathological significance of LAT1 and 4F2hc. PATIENTS AND METHODS: Tissues from 126 patients with GEP-NENs were collected between August 2007 and August 2019 at our institution. We evaluated LAT1 and 4F2hc expression by immunohistochemistry, and examined their clinical significance. RESULTS: No statistically significant associations were observed between LAT1 expression and the different NENs. Expression of 4F2hc was significantly different between neuroendocrine tumour (NET)-G1, NET-G2, and NET-G3 (p=0.029), and was significantly associated with vascular invasion (p=0.044) and the Ki-67 index (p=0.042). CONCLUSION: No association between LAT1 expression and malignant features in GEP-NENs was observed. However, an association between 4F2hc expression and the potential of malignancy in GEP-NENs was evident.
BACKGROUND/AIM: Little is known about the expression of L-type amino acid transporter 1 (LAT1) and 4F2hc in gastroenteropancreatic-neuroendocrine neoplasms (GEP-NENs). Hence, we conducted a study to verify the clinicopathological significance of LAT1 and 4F2hc. PATIENTS AND METHODS: Tissues from 126 patients with GEP-NENs were collected between August 2007 and August 2019 at our institution. We evaluated LAT1 and 4F2hc expression by immunohistochemistry, and examined their clinical significance. RESULTS: No statistically significant associations were observed between LAT1 expression and the different NENs. Expression of 4F2hc was significantly different between neuroendocrine tumour (NET)-G1, NET-G2, and NET-G3 (p=0.029), and was significantly associated with vascular invasion (p=0.044) and the Ki-67 index (p=0.042). CONCLUSION: No association between LAT1 expression and malignant features in GEP-NENs was observed. However, an association between 4F2hc expression and the potential of malignancy in GEP-NENs was evident.
Authors: James C Yao; Manisha H Shah; Tetsuhide Ito; Catherine Lombard Bohas; Edward M Wolin; Eric Van Cutsem; Timothy J Hobday; Takuji Okusaka; Jaume Capdevila; Elisabeth G E de Vries; Paola Tomassetti; Marianne E Pavel; Sakina Hoosen; Tomas Haas; Jeremie Lincy; David Lebwohl; Kjell Öberg Journal: N Engl J Med Date: 2011-02-10 Impact factor: 91.245
Authors: James C Yao; Nicola Fazio; Simron Singh; Roberto Buzzoni; Carlo Carnaghi; Edward Wolin; Jiri Tomasek; Markus Raderer; Harald Lahner; Maurizio Voi; Lida Bubuteishvili Pacaud; Nicolas Rouyrre; Carolin Sachs; Juan W Valle; Gianfranco Delle Fave; Eric Van Cutsem; Margot Tesselaar; Yasuhiro Shimada; Do-Youn Oh; Jonathan Strosberg; Matthew H Kulke; Marianne E Pavel Journal: Lancet Date: 2015-12-17 Impact factor: 79.321
Authors: K Kaira; Y Sunose; K Arakawa; T Ogawa; N Sunaga; K Shimizu; H Tominaga; N Oriuchi; H Itoh; S Nagamori; Y Kanai; A Segawa; M Furuya; M Mori; T Oyama; I Takeyoshi Journal: Br J Cancer Date: 2012-07-17 Impact factor: 7.640
Authors: K Kaira; N Oriuchi; H Imai; K Shimizu; N Yanagitani; N Sunaga; T Hisada; S Tanaka; T Ishizuka; Y Kanai; H Endou; T Nakajima; M Mori Journal: Br J Cancer Date: 2008-02-05 Impact factor: 7.640